| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 37, 1379-1383, Copyright © 1991 by American Association for Clinical Chemistry
R Molina, X Filella, J Bruix, P Mengual, J Bosch, X Calvet, J Jo and AM Ballesta
Laboratory of Clinical Biochemistry, Hospital Clinico Provincial, School of Medicine, Barcelona, Spain.
Serum concentrations of cancer antigen 125 (CA 125) were determined for 373 patients with various liver diseases: 57 with acute hepatitis, 57 with chronic hepatitis, 244 with liver cirrhosis (86 compensated and 158 decompensated), and 15 with primary liver cancer. The antigen was measured simultaneously in the serum and ascitic fluid of 46 of the patients with liver cirrhosis and sequentially in the serum and ascitic fluid of another 25 cirrhotics treated with paracentesis and (or) diuretics. Abnormal results for CA 125 were detected in sera from 4% of the patients with acute or chronic hepatitis, 60% of the patients with liver cirrhosis, and 67% of the patients with primary liver cancer. The main factor associated with abnormal serum concentrations of this antigen was the presence of ascites, with pathological CA 125 values in 94% of patients with ascites without jaundice (mean 566 +/- 528 arb. units/mL), compared with only 40% of patients with jaundice and without ascites (mean 40.1 +/- 28.5 arb. units/mL) (P less than 0.001). High concentrations of CA 125 were mainly associated with spontaneous bacterial peritonitis. The serum concentration of CA 125 decreased after treatment with paracentesis, but increased in patients treated with diuretics rather than paracentesis. The release of this antigen in liver cirrhosis appears to be independent of the liver disorder and, rather, results from peritoneal synthesis of this antigen.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  F. Kosar, Y. Aksoy, G. Ozguntekin, I. Ozerol, and E. Varol Relationship between cytokines and tumour markers in patients with chronic heart failure Eur J Heart Fail, May 1, 2006; 8(3): 270 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kalambokis, A. Kostoula, M. Economou, and E. V. Tsianos Tumor Necrosis Factor-{alpha}-Related Intraperitoneal Release of CA 125 in Cirrhotic Patients with Sterile Ascites Clin. Chem., November 1, 2005; 51(11): 2207 - 2208. [Full Text] [PDF]
|
|
|
|
|
|
N. T. Kouris, I. D. Zacharos, D. D. Kontogianni, G. S. Goranitou, M. D. Sifaki, H. E. Grassos, E. M. Kalkandi, and D. K. Babalis The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters Eur J Heart Fail, March 2, 2005; 7(2): 199 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Baron, C. H. Boardman, J. M. Lafky, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 306 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Devarbhavi, D. Kaese, A. W. Williams, J. Rakela, G. G. Klee, and P. S. Kamath Cancer Antigen 125 in Patients With Chronic Liver Disease Mayo Clin. Proc., June 1, 2002; 77(6): 538 - 541. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
